iRepertoire and Sequenta join forces on blood cancer testing

SOUTH SAN FRANCISCO, Calif. and HUNTSVILLE, Ala. — Sequenta and iRepertoire announced today that Sequenta has gained exclusive rights to the iRepertoire intellectual property on novel methods of immune cell sequencing for minimal residual disease (MRD) testing. This intellectual property complements Sequenta’s existing patents on MRD, including its proprietary LymphoSIGHT™ technology. The agreement reinforces Sequenta’s patent portfolio, which strengthens Sequenta’s ability to provide future products and new features and solidifies the company’s position as the MRD market leader.

“This agreement demonstrates our continued commitment to providing the most sensitive and best validated platform for measuring residual disease in lymphoid cancer,” said Tom Willis, chief executive officer of Sequenta. “The complementary technology, intellectual property estate and alignment with Dr. Jian Han, one of the pioneers in immune profiling, will strengthen our position in the MRD testing field and further differentiate our product offerings.”

The rest of the release can be read on the Business Wire website.